Blogs | | Ideally, corneal cross-linking is offered as an early intervention for keratoconus as soon as there is evidence of progression and before significant vision loss or ectasia. But what if you see a patient with a cornea that is already quite thin?
NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022 Topline Data from ZETA-1 Phase 2b Trial of Oral APX3330 Expected in Early.
Highlighting latest clinical findings, including comparative efficacy for ocular itch relief between Pataday Once Daily Relief Extra Strength and an oral antihistamine Forthcoming innovations